Dermata Therapeutics (DRMA)
(Delayed Data from NSDQ)
$3.62 USD
+0.18 (5.13%)
Updated May 30, 2024 03:56 PM ET
After-Market: $3.55 -0.07 (-1.93%) 6:24 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
DRMA 3.62 +0.18(5.13%)
Will DRMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DRMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DRMA
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
DRMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for DRMA
12 Health Care Stocks Moving In Tuesday's After-Market Session
Dermata Therapeutics (DRMA) Receives a Buy from Maxim Group
Dermata Therapeutics GAAP EPS of -$0.47 beats by $5.83
Dermata Therapeutics announces exercise of warrants for $2.66M
Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules